Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycerin SCHEMBL6753203 | 0.80 | LMNA (1.00) | LMNAALDH1A1THRBTDP1MAPT | |
| Glycerin SCHEMBL8080917 | 0.80 | LMNA (1.00) | LMNAALDH1A1THRBTDP1MAPT | |
| Glycerin SCHEMBL14278797 | 0.80 | — | — | |
| Glycerin SCHEMBL14278795 | 0.80 | — | — | |
| Glycerin SCHEMBL3418854 | 0.80 | LMNA (1.00) | LMNAALDH1A1THRBTDP1MAPT | |
| Glycerin SCHEMBL10453101 | 0.80 | LMNA (1.00) | LMNAALDH1A1THRBTDP1MAPT | |
| Glycerin SCHEMBL9439059 | 0.80 | LMNA (1.00) | LMNAALDH1A1THRBTDP1MAPT | |
| Glycerin SCHEMBL797 | 0.80 | — | — | |
| Glycerin SCHEMBL5610362 | 0.80 | LMNA (1.00) | LMNAALDH1A1THRBTDP1MAPT | |
| Glycerin SCHEMBL29907853 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10196641-B2 | Modified oligonucleotides for telomerase inhibition | GERON CORPORATION (US) | 2019-02-05 | — | — | US | disclosed |
| US-9657296-B2 | Modified oligonucleotides for telomerase inhibition | GERON CORPORATION (US) | 2017-05-23 | — | — | US | disclosed |
| US-20170130225-A1 | MODIFIED OLIGONUCLEOTIDES FOR TELOMERASE INHIBITION | GERON CORPORATION | 2017-05-11 | — | — | US | disclosed |
| US-9404112-B2 | Modified oligonucleotides for telomerase inhibition | GERON CORPORATION (US) | 2016-08-02 | — | — | US | disclosed |
| US-9388416-B2 | Modified oligonucleotides for telomerase inhibition | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2016-07-12 | — | — | US | disclosed |
| US-9388415-B2 | Modified oligonucleotides for telomerase inhibition | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2016-07-12 | — | — | US | disclosed |
| US-20150376624-A1 | Modified Oligonucleotides for Telomerase Inhibition | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2015-12-31 | — | — | US | disclosed |
| US-20150322437-A1 | Modified Oligonucleotides for Telomerase Inhibition | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2015-11-12 | — | — | US | disclosed |
| US-20150322438-A1 | Modified Oligonucleotides for Telomerase Inhibition | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2015-11-12 | — | — | US | disclosed |
| US-20130065950-A1 | MODIFIED OLIGONUCLEOTIDES FOR TELOMERASE INHIBITION | GERON CORPORATION | 2013-03-14 | — | — | US | disclosed |
| US-20120329858-A1 | MODIFIED OLIGONUCLEOTIDES FOR TELOMERASE INHIBITION | GERON CORPORATION | 2012-12-27 | — | — | US | disclosed |
| US-20120129918-A1 | MODIFIED OLIGONUCLEOTIDES FOR TELOMERASE INHIBITION | GERON CORPORATION | 2012-05-24 | — | — | US | disclosed |
| US-20090286853-A1 | MODIFIED OLIGONUCLEOTIDES FOR TELOMERASE INHIBITION | GERON CORPORATION | 2009-11-19 | — | — | US | disclosed |
| US-7494982-B2 | Modified oligonucleotides for telomerase inhibition | GERON CORPORATION (US) | 2009-02-24 | — | — | US | disclosed |
| CN-100393209-C | Modified oligonucleotides for telomerase inhibition | GERON CORP (US) | 2008-06-11 | — | — | CN | disclosed |
| CN-1849069-A | Modified oligonucleotides for telomerase inhibition | GERON CORP (US) | 2006-10-18 | — | — | CN | disclosed |
| US-20050113325-A1 | Modified oligonucleotides for telomerase inhibition | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065950-A1 | MODIFIED OLIGONUCLEOTIDES FOR TELOMERASE INHIBITION | TERT, TRDMT1, TERF2 | LMNA 1176/4885ALDH1A1 2034/4885THRB 743/4885 |
| US-20120129918-A1 | MODIFIED OLIGONUCLEOTIDES FOR TELOMERASE INHIBITION | TERT, TRDMT1, TERF2 | LMNA 1176/4885ALDH1A1 2034/4885THRB 743/4885 |
| US-20050113325-A1 | Modified oligonucleotides for telomerase inhibition | TERT, TRDMT1, TERF2 | LMNA 1176/4885ALDH1A1 2034/4885THRB 743/4885 |
| US-10196641-B2 | Modified oligonucleotides for telomerase inhibition | TERT, TRDMT1, TERF2 | LMNA 1176/4885ALDH1A1 2034/4885THRB 743/4885 |
| US-20090286853-A1 | MODIFIED OLIGONUCLEOTIDES FOR TELOMERASE INHIBITION | TERT, TRDMT1, TERF2 | LMNA 1176/4885ALDH1A1 2034/4885THRB 743/4885 |
| US-20120329858-A1 | MODIFIED OLIGONUCLEOTIDES FOR TELOMERASE INHIBITION | TERT, TRDMT1, TERF2 | LMNA 1176/4885ALDH1A1 2034/4885THRB 743/4885 |
| US-20150376624-A1 | Modified Oligonucleotides for Telomerase Inhibition | TERT, TRDMT1, TERF2 | LMNA 1176/4885ALDH1A1 2034/4885THRB 743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.